Navitoclax (ABT-263)

Catalog No.S1001

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Cited by 153 Publications

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Cell Metab, 2019, 30(1):129-142

PubMed: 31155496 ( click the link to review the publication )

Cancer Discov, 2018, 8(12):1598-1613

PubMed: 30254092 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(2):112-117

PubMed: 29200207 ( click the link to review the publication )

Cancer Cell, 2017, 32(4):490-505.e10

PubMed: 29017059 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):407-414.e4

PubMed: 28017795 ( click the link to review the publication )

Nature, 2016, 538(7626):477-482

PubMed: 27760111 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Sci Adv, 2019, 5(7):eaau9433

PubMed: 31392262 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e10769

PubMed: 31468706 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0775

PubMed: 31806643 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Thyroid, 2019, 29(4):540-548

PubMed: 30869573 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30860026 ( click the link to review the publication )

Oncogene, 2019, 38(1):47-59

PubMed: 30076411 ( click the link to review the publication )
Br J Pharmacol, 2019, 10.1111/bph.14773

PubMed: 31222722 ( click the link to review the publication )

J Med Chem, 2019, 62(15):6913-6924

PubMed: 31339316 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

FASEB J, 2019, 10.1096/fj.201900815RR

PubMed: 31408372 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):86

PubMed: 30867061 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31801186 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

J Biol Chem, 2019, 294(3):875-886

PubMed: 30482844 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:218

PubMed: 31462891 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:222

PubMed: 31467488 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

Cell Biosci, 2019, 9:60

PubMed: 31367332 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

Photodiagnosis Photodyn Ther, 2019, 10.1016/j.pdpdt.2019.08.016

PubMed: 31430575 ( click the link to review the publication )

Cancer Biomark, 2019, 24(1):51-59

PubMed: 30614795 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 42(3):287-301

PubMed: 30859392 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

J Allergy Clin Immunol, 2018, 142(5):1647-1650.e3

PubMed: 30048671 ( click the link to review the publication )

Nat Commun, 2018, 9(1):215

PubMed: 29335437 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10195-10215

PubMed: 30239926 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )
Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):713

PubMed: 29915306 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):21

PubMed: 29343814 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):907

PubMed: 30185782 ( click the link to review the publication )

Stem Cell Res Ther, 2018, 9(1):108

PubMed: 29669575 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Biochemical Pharmacology, 2018, 10.1016/j.bcp.2018.01.031

PubMed: ( click the link to review the publication )

Mar Drugs, 2018, 16(12)

PubMed: 30572618 ( click the link to review the publication )

Biomed Pharmacother, 2018, 107:139-145

PubMed: 30086460 ( click the link to review the publication )

Cell Cycle, 2018, 17(17):2175-2186

PubMed: 30198376 ( click the link to review the publication )

Toxicol In Vitro, 2018, 46:229-236

PubMed: 28947240 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1940

PubMed: 29208897 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2476-2487

PubMed: 28209615 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )
Mol Cancer Ther, 2017, 16(10):2178-2190

PubMed: 28611106 ( click the link to review the publication )

Cell Commun Signal, 2017, 15(1):16

PubMed: 28464919 ( click the link to review the publication )

Dis Model Mech, 2017, 10(9):1109-1115

PubMed: 28883017 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(12):1632-1641

PubMed: 28713162 ( click the link to review the publication )

Int J Oncol, 2017, 10.3892/ijo.2017.3914

PubMed: 28350129 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1141-1149

PubMed: 28885267 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Nat Microbiol, 2016, 1:15034

PubMed: 27572165 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996 ( click the link to review the publication )

Leukemia, 2016, 30(2):351-60

PubMed: 26488112 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Int J Cancer, 2016, 138(2):507-14

PubMed: 26260669 ( click the link to review the publication )

Anal Chem, 2016, 88(16):8050-7

PubMed: 27425825 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(1):35-45

PubMed: 26483423 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(11):2915-2926

PubMed: 27913811 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Cell Cycle, 2016, 15(3):394-402

PubMed: 26694174 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164250

PubMed: 27723829 ( click the link to review the publication )
Biochem Biophys Res Commun, 2016, 478(4):1792-7

PubMed: 27613092 ( click the link to review the publication )

J Biomol Screen, 2016, 21(7):680-8

PubMed: 27245141 ( click the link to review the publication )

Mol Med Rep, 2016, 13(1):403-11

PubMed: 26548896 ( click the link to review the publication )

Data Brief, 2016, 6:710-4

PubMed: 26958630 ( click the link to review the publication )

Oncotarget, 2016, 7(1):845-59

PubMed: 26625317 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

Ann Surg Oncol, 2015, 22(9):3079-86

PubMed: 25524010 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120913

PubMed: 25811469 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116998

PubMed: 25615615 ( click the link to review the publication )

Microvasc Res, 2015, 101:72-81

PubMed: 26122935 ( click the link to review the publication )

Oncol Lett, 2015, 10(2):829-834

PubMed: 26622578 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27388-402

PubMed: 26317541 ( click the link to review the publication )

Oncotarget, 2015, 6(17):15551-65

PubMed: 26036632 ( click the link to review the publication )

J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203 ( click the link to review the publication )
Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108371

PubMed: 25289887 ( click the link to review the publication )

PLoS One, 2014, ;9(6):e99404

PubMed: 24901320 ( click the link to review the publication )

Blood, 2013, 121(10):1850-7

PubMed: 23303820 ( click the link to review the publication )

Blood, 2013, 122(9):1587-98

PubMed: 23881917 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116 ( click the link to review the publication )

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e883

PubMed: 24157877 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Neoplasia, 2013, 15(5):568-78

PubMed: 23633928 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2960-8

PubMed: 23974105 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64051

PubMed: 23691145 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 434(3):695-700

PubMed: 23602897 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )
Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819 ( click the link to review the publication )

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522 ( click the link to review the publication )

Transfusion, 2012, 52(10):2094-103

PubMed: 22320126 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(12):3956-68

PubMed: 21652541 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24590

PubMed: 21931768 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Targets

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. ^[1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. ^[1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	M2PJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zlTGlEPTB;MD6wNFY3QSEQvF2=	M{j2N3NCVkeHUh?=
MV-4-11	NF\uOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrKcnlTUUN3ME2wMlAyPTh4IN88US=>	NUnyNllVW0GQR1XS
NKM-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHRUld4UUN3ME2wMlAyPjl7IN88US=>	MlL6V2FPT0WU
ML-2	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PhcmlEPTB;MD6wNVk5OyEQvF2=	M37VRnNCVkeHUh?=
BV-173	NIX3N4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfpTWM2OD1yLkCyN\|E1KM7:TR?=	MX\TRW5ITVJ?
RS4-11	NFzqWZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwMEK1PFch\|ryP	NXTtVmdsW0GQR1XS
HL-60	M1HIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwMEK5NFgh\|ryP	MkjEV2FPT0WU
KY821	NF\KcmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\RfGlEPTB;MD6wNlk4PSEQvF2=	NUPGfndMW0GQR1XS
ECC10	MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{mxTGlEPTB;MD6wN\|c6OiEQvF2=	MWHTRW5ITVJ?
NCI-H720	NF3Ze\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrmTWM2OD1yLkC0NFEyKM7:TR?=	MVnTRW5ITVJ?
QIMR-WIL	M3HmW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rLNGlEPTB;MD6wOFI5PyEQvF2=	NFzsV45USU6JRWK=
KG-1	M2nnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoS2TWM2OD1yLkC0OFg3KM7:TR?=	NGrLRmRUSU6JRWK=
TGW	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPPTWM2OD1yLkC0OlM{KM7:TR?=	NYniOGZrW0GQR1XS
ATN-1	MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rGR2lEPTB;MD6wOFc{OyEQvF2=	MnHpV2FPT0WU
RH-18	NF3vOmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPad5dKSzVyPUCuNFYxPDhizszN	MnG5V2FPT0WU
EW-18	M{fCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDLW5hKSzVyPUCuNFY5PDFizszN	NGHtO2FUSU6JRWK=
NB17	NIr1NWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;rNGlEPTB;MD6wO\|EzPCEQvF2=	NULtWnpvW0GQR1XS
SK-NEP-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTBwMEeyNVMh\|ryP	MXLTRW5ITVJ?
P12-ICHIKAWA	NFrIfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;sTWM2OD1yLkC3O\|c5KM7:TR?=	M1T2RXNCVkeHUh?=
KARPAS-45	MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMEe4NVUh\|ryP	MX\TRW5ITVJ?
EW-3	NX\lXmZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkSwTWM2OD1yLkC4NFU{KM7:TR?=	MYHTRW5ITVJ?
NB13	NGC2XIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLXTWM2OD1yLkC4NlA{KM7:TR?=	Mkm2V2FPT0WU
NCI-H209	MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMEi3NFQh\|ryP	MlLwV2FPT0WU
NCI-H1092	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{SwOmlEPTB;MD6xNFI4PSEQvF2=	MmPOV2FPT0WU
NH-12	NV3vUlRQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTLTWM2OD1yLkGwO\|Q1KM7:TR?=	NF2yPVZUSU6JRWK=
697	MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\rflNKSzVyPUCuNVA5OzlizszN	MXPTRW5ITVJ?
KE-37	NFLQcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPPV21KSzVyPUCuNVE{PyEQvF2=	MXfTRW5ITVJ?
MOLT-4	NH7DOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHITVN[UUN3ME2wMlE2OTZ7IN88US=>	MlO1V2FPT0WU
CHP-134	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHCTWM2OD1yLkG2N\|A3KM7:TR?=	MkXmV2FPT0WU
D-283MED	M1vJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPjSYpKSzVyPUCuNVc3QDZizszN	NGDiSINUSU6JRWK=
LU-135	M4P2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwMUi1OVIh\|ryP	M3\mS3NCVkeHUh?=
LU-134-A	NXvTTZNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfUTWM2OD1yLkG4OlcyKM7:TR?=	M4f6PHNCVkeHUh?=
EM-2	NVvONJZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rYc2lEPTB;MD6xPVkyQCEQvF2=	MVLTRW5ITVJ?
LU-139	MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vI[WlEPTB;MD6yNFQ6QCEQvF2=	M3S5VnNCVkeHUh?=
ALL-PO	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LMTGlEPTB;MD6yNVk5QCEQvF2=	NXTYNpMyW0GQR1XS
NB12	M4\nemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlT5TWM2OD1yLkKzNVE2KM7:TR?=	M4\qPHNCVkeHUh?=
KP-N-YN	MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\3TWM2OD1yLkKzOVc{KM7:TR?=	NVmz[mVjW0GQR1XS
BEN	NH3SVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkSxTWM2OD1yLkKzPVY5KM7:TR?=	M2TZNnNCVkeHUh?=
HCC1569	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXwTWM2OD1yLkK1NVA3KM7:TR?=	NXj0UG5JW0GQR1XS
HuO9	Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnjTWM2OD1yLkK2O\|E2KM7:TR?=	MWLTRW5ITVJ?
WM-115	NFfSNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn70TWM2OD1yLkK3O\|M5KM7:TR?=	M2TzPXNCVkeHUh?=
CCRF-CEM	NHfMN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvrRZVzUUN3ME2wMlM{PTJ7IN88US=>	MV\TRW5ITVJ?
IST-SL1	NIO5c5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;BfoVKSzVyPUCuN\|U{PDNizszN	MYLTRW5ITVJ?
BE-13	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\kTWM2OD1yLkO2OFU6KM7:TR?=	MnOzV2FPT0WU
COR-L88	M3TTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwM{[1OEDPxE1?	NV\mWGhQW0GQR1XS
DOHH-2	M4fsc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVu3WWhjUUN3ME2wMlQyODJ\|IN88US=>	MnrkV2FPT0WU
A704	MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nRZmlEPTB;MD60NlY4KM7:TR?=	NFHPcGtUSU6JRWK=
KNS-81-FD	MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4ntcmlEPTB;MD60OFAyPyEQvF2=	NInCVYtUSU6JRWK=
RPMI-8226	NUTXboZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTQT4dKSzVyPUCuOFU3PTJizszN	M2[z[XNCVkeHUh?=
TGBC24TKB	MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDjOo85UUN3ME2wMlQ2Pzd6IN88US=>	MlrmV2FPT0WU
NCI-H1304	NWHyNGx{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nad2lEPTB;MD60OlE2PyEQvF2=	MmrEV2FPT0WU
MOLT-13	M1T5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rDcWlEPTB;MD60OlYyOyEQvF2=	NGPKeZJUSU6JRWK=
EW-22	MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjjd\|M5UUN3ME2wMlQ3PjdzIN88US=>	MWTTRW5ITVJ?
MS-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fZNGlEPTB;MD60Olk{OyEQvF2=	NULCe3ppW0GQR1XS
RMG-I	MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fWSWlEPTB;MD60PVQ3PCEQvF2=	M2fUXXNCVkeHUh?=
NTERA-S-cl-D1	MkPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjKbW1PUUN3ME2wMlUxODF7IN88US=>	NEjnV3BUSU6JRWK=
NCI-H1048	M4TE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XJZWlEPTB;MD61NFk2OyEQvF2=	MX;TRW5ITVJ?
SW1417	Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLMZ\|BKSzVyPUCuOVU1OzhizszN	MofQV2FPT0WU
DB	MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXwTWM2OD1yLkW3NFgh\|ryP	MXHTRW5ITVJ?
MEG-01	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLTOmp[UUN3ME2wMlU5OzJizszN	NYLJ[2pZW0GQR1XS
EW-13	NYr4fZFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIflfJVKSzVyPUCuOVg{PDFizszN	MlfrV2FPT0WU
LAMA-84	NWrzd4tvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwNUmyNFch\|ryP	M2TUeXNCVkeHUh?=
J-RT3-T3-5	M3\BTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHoTWM2OD1yLk[wPFA5KM7:TR?=	MYnTRW5ITVJ?
MOLT-16	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfsTnBKSzVyPUCuOlUzPjRizszN	NIjjOZNUSU6JRWK=
DU-4475	Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXH4cGl6UUN3ME2wMlY2PDJ5IN88US=>	NF;NZmxUSU6JRWK=
HAL-01	MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwN{K1OFkh\|ryP	MUDTRW5ITVJ?
RD	NVqwfG1JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nHRWlEPTB;MD63OVg6QSEQvF2=	NVz1eXExW0GQR1XS
OAW-28	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;YWWlEPTB;MD63PFM4KM7:TR?=	M2PUcnNCVkeHUh?=
HCC38	NELSU\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjO[npPUUN3ME2wMlgxOTlizszN	MoTJV2FPT0WU
NMC-G1	M4C4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXhTWM2OD1yLkixNVIyKM7:TR?=	M{izU3NCVkeHUh?=
EW-16	M{X6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTzTWM2OD1yLkixN\|I5KM7:TR?=	MmrSV2FPT0WU
DU-145	M2npPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwOEm5NlMh\|ryP	NV\ZOmlCW0GQR1XS
HPAF-II	NFn2U4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3qTWM2OD1yLkmyOlI5KM7:TR?=	MmXWV2FPT0WU
A427	MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2[xcWlEPTB;MD65N\|AzOiEQvF2=	MV\TRW5ITVJ?
PA-1	M2X0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmK1TWM2OD1yLkm1OlQzKM7:TR?=	NYrzOlFHW0GQR1XS
OAW-42	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3L1dmlEPTB;MD65OlE1PiEQvF2=	M3[0bHNCVkeHUh?=
L-428	MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\yTGlEPTB;MT6wNVI2KM7:TR?=	MXXTRW5ITVJ?
COLO-824	M3vJVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXzTHlUUUN3ME2xMlAyPzB6IN88US=>	MW\TRW5ITVJ?
P30-OHK	M4X5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;meJJKSzVyPUGuNFQ3QDhizszN	M4LmT3NCVkeHUh?=
NCI-H2170	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTFwME[yN{DPxE1?	M4L4NnNCVkeHUh?=
HCC2998	NUjLdIUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;YU4xKSzVyPUGuNFcyOzVizszN	NXXjTVNlW0GQR1XS
NB14	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jjO2lEPTB;MT6xN\|c1QCEQvF2=	NWLhNot{W0GQR1XS
TGBC1TKB	NGq2NotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHoe4ljUUN3ME2xMlE1OTV{IN88US=>	M{fBUnNCVkeHUh?=
KP-N-YS	NXrmeJFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LpcWlEPTB;MT6xOlI{PiEQvF2=	NITx[3hUSU6JRWK=
CAL-120	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLTUWN[UUN3ME2xMlE3PDJ7IN88US=>	MljNV2FPT0WU
SBC-1	NWPqPXVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHU[2NKSzVyPUGuNVkxPTNizszN	M1W3SXNCVkeHUh?=
C32	MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nSZWlEPTB;MT6xPVA5QCEQvF2=	M1GwR3NCVkeHUh?=
HCC2157	MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrQTWM2OD1zLkG5OFk1KM7:TR?=	NFv2dFZUSU6JRWK=
COLO-792	M3vabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnEUJNKSzVyPUGuNlAxPzFizszN	NHPIVpFUSU6JRWK=
ES7	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTFwMke5OVEh\|ryP	MorMV2FPT0WU
HEL	M4PjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYixOIk3UUN3ME2xMlMyODJ7IN88US=>	NYH1PGtyW0GQR1XS
ES4	M{KyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTFwM{S5PVgh\|ryP	NF36RmNUSU6JRWK=
NCI-SNU-1	NUS2W45OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTFwM{[1OVUh\|ryP	MVrTRW5ITVJ?
MDA-MB-415	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zFSGlEPTB;MT6zPFg2KM7:TR?=	NY\BfHBuW0GQR1XS
NCI-H2342	NHzo[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXCOoR{UUN3ME2xMlQxOjZ7IN88US=>	NYjFXFVZW0GQR1XS
NB69	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33GRWlEPTB;MT60OlI4OSEQvF2=	MniyV2FPT0WU
D-247MG	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojtTWM2OD1zLkWxNVIzKM7:TR?=	M{TZWnNCVkeHUh?=
SCC-4	NET6VWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFn2fW5KSzVyPUGuOVk5QDdizszN	NEnhXIhUSU6JRWK=
HuH-7	MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1v4dmlEPTB;MT62O\|I6OyEQvF2=	MUTTRW5ITVJ?
A388	MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\IUGlEPTB;MT62PFczPCEQvF2=	NFnkNW9USU6JRWK=
Calu-3	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\nd2VUUUN3ME2xMlcxPjl5IN88US=>	NX[yfZZkW0GQR1XS
NCI-H1648	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;l[29wUUN3ME2xMlcyPDF6IN88US=>	MVXTRW5ITVJ?
NCI-H2052	NVi4TXNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3pTWM2OD1zLkeyNlAyKM7:TR?=	M3XEfXNCVkeHUh?=
Ramos-2G6-4C10	NXXCO5dRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnGeI54UUN3ME2xMlc{PjV4IN88US=>	M{TDV3NCVkeHUh?=
DEL	NXfST2pyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTCTWM2OD1zLke0OlkzKM7:TR?=	M4H2RnNCVkeHUh?=
SNU-423	NIDjbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;YT5hKSzVyPUGuO\|gyPTdizszN	M4nqOnNCVkeHUh?=
COR-L23	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTFwN{m4O\|Qh\|ryP	MnT6V2FPT0WU
OMC-1	NGrVepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTFwOE[wNVYh\|ryP	MUHTRW5ITVJ?
EW-11	NV;KN\|ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfxU4lKSzVyPUGuPVU3PTdizszN	NInxdppUSU6JRWK=
HSC-3	NYriclAxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7lOnJKSzVyPUGuPVY{PjVizszN	NIPUT\|VUSU6JRWK=
MLMA	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTFwOU[2O\|ch\|ryP	NETYWnJUSU6JRWK=
RCM-1	MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTJwMECzPVkh\|ryP	MlHLV2FPT0WU
MFE-280	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7aTWM2OD1{LkCyPFQ5KM7:TR?=	MnPpV2FPT0WU
ES8	NHzlR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzjc4d6UUN3ME2yMlI2PDdzIN88US=>	MoDXV2FPT0WU
TE-11	NFLTOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\YTWM2OD1{LkK5OFc{KM7:TR?=	Ml3QV2FPT0WU
HuO-3N1	M{fz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmmwTWM2OD1{LkS4O\|gh\|ryP	NUGwWmZRW0GQR1XS
MHH-NB-11	Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWT1[Y5lUUN3ME2yMlUyOTV6IN88US=>	NFu4TFVUSU6JRWK=
TGBC11TKB	Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPLN2hJUUN3ME2yMlU4PjhzIN88US=>	NUfyemlGW0GQR1XS
HOP-92	NWTxWnEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTJwNUi3OFMh\|ryP	Mmr5V2FPT0WU
IGR-1	NUjHbGd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTJwNkKwN\|Uh\|ryP	NXGxZo1RW0GQR1XS
GOTO	NWHjUIpCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTJwNkWzO\|ch\|ryP	NXmyT\|NzW0GQR1XS
NCI-H1650	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTDZ5RNUUN3ME2yMlczOjF3IN88US=>	NUfOUZZFW0GQR1XS
NCI-H1581	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfNfIZKSzVyPUKuO\|k3QDFizszN	NFvQfmZUSU6JRWK=
NCI-H2405	NGGx[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXvTWM2OD1{LkiyO\|gzKM7:TR?=	NHnOZoFUSU6JRWK=
U-118-MG	NH7iZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTJwOU[0PVEh\|ryP	MmrWV2FPT0WU
DoTc2-4510	M4nHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfFd3BKSzVyPUOuNFE1OTdizszN	NWXGOpdNW0GQR1XS
NCI-H596	MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWf2bIV[UUN3ME2zMlA1QTl5IN88US=>	M{W1OnNCVkeHUh?=
MPP-89	NHPIOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTuTWM2OD1\|LkC1OlY3KM7:TR?=	MoPWV2FPT0WU
GCIY	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmS3TWM2OD1\|LkKwOFkyKM7:TR?=	MljoV2FPT0WU
SW626	M{LSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLzTWM2OD1\|LkK0OVQ{KM7:TR?=	MYjTRW5ITVJ?
OCI-AML2	MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTNwM{GyO\|Ih\|ryP	NV7hOGFYW0GQR1XS
NBsusSR	NX36dVdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTNwM{S5N\|gh\|ryP	NGH4Rm1USU6JRWK=
AN3-CA	NWDkcIs2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTNwNESyN\|gh\|ryP	MkHTV2FPT0WU
EFM-19	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfKUIZTUUN3ME2zMlQ5OzN7IN88US=>	NF72dZJUSU6JRWK=
RVH-421	NWXmTZNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUi4dIRvUUN3ME2zMlU3QDd5IN88US=>	NGDTVHhUSU6JRWK=
5637	M1;yVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTTTJczUUN3ME2zMlYyOTB\|IN88US=>	MmjwV2FPT0WU
PANC-08-13	MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTNwNkO0O\|Ih\|ryP	M{\zW3NCVkeHUh?=
H9	NVHMS4htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2OycmlEPTB;Mz62O\|E1PCEQvF2=	MWfTRW5ITVJ?
KARPAS-299	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTNwNkezOlEh\|ryP	NYjBV3NNW0GQR1XS
TE-5	M33TUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHNTWM2OD1\|LkewO\|A6KM7:TR?=	MVvTRW5ITVJ?
NOS-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTNwN{m4N\|Qh\|ryP	MYnTRW5ITVJ?
HH	NXmxZlFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnYPYVKSzVyPUOuPFM5PjhizszN	NYnnUIpnW0GQR1XS
769-P	NEfnNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvjO5lKSzVyPUOuPFk2OSEQvF2=	Mn;vV2FPT0WU
CHP-212	M1nhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmCwTWM2OD1\|LkmyOVQ6KM7:TR?=	MkPZV2FPT0WU
NCI-H82	MoPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLqTWM2OD1\|Lkm1PVM3KM7:TR?=	NUHCbWJDW0GQR1XS
Mo-T	NEKzUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTRwMESzNVIh\|ryP	NHfTeFZUSU6JRWK=
BB65-RCC	MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDFTWM2OD12LkC0N\|k6KM7:TR?=	Mor4V2FPT0WU
SW1990	NWLJ[Jh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLDSpBwUUN3ME20MlA2QTB6IN88US=>	NGWxdY1USU6JRWK=
LK-2	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3:wcGlEPTB;ND6xNVI6OyEQvF2=	Mnq3V2FPT0WU
ES5	NEfTOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXFe5ZKSzVyPUSuNVM6QDVizszN	M2LBfnNCVkeHUh?=
JVM-3	Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn20TWM2OD12LkG4NlIzKM7:TR?=	NIXYVmpUSU6JRWK=
RPMI-7951	M3\4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrRTWM2OD12LkKyOFE{KM7:TR?=	M2\vVHNCVkeHUh?=
Calu-6	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX3UcFZvUUN3ME20MlI4QDhzIN88US=>	MWjTRW5ITVJ?
LC-2-ad	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTRwMkm1Olgh\|ryP	NGrjVYFUSU6JRWK=
SW954	NIfhPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXrTWM2OD12LkK5OlYh\|ryP	M4P2e3NCVkeHUh?=
H-EMC-SS	NFf6NHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTRwM{G4N\|Eh\|ryP	M1LDNXNCVkeHUh?=
ES3	MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVToO451UUN3ME20MlM2PDRzIN88US=>	MVnTRW5ITVJ?
no-11	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTRwM{W1OVQh\|ryP	NUD3cY5rW0GQR1XS
LAN-6	NYm2eW1PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3yyVGlEPTB;ND60OVE5QSEQvF2=	MlTDV2FPT0WU
FTC-133	NELPbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUSxSY42UUN3ME20MlU{QTVizszN	NUDzZoF1W0GQR1XS
8505C	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlH6TWM2OD12LkW0NlMh\|ryP	MmfPV2FPT0WU
SW620	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTRwNUewOVch\|ryP	NX7SU3ZtW0GQR1XS
BCPAP	NHHFOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTRwNkO0PFEh\|ryP	M4DuTHNCVkeHUh?=
SK-LU-1	NWHzcVZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlu4TWM2OD12Lk[2NFg6KM7:TR?=	M{PITHNCVkeHUh?=
NCI-H1623	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEe5VoxKSzVyPUSuO\|AzOjhizszN	MmHoV2FPT0WU
C2BBe1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTOWZhqUUN3ME20Mlc1ODB6IN88US=>	MnvDV2FPT0WU
GP5d	NXXVfXhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofFTWM2OD12Lke4N\|g5KM7:TR?=	MlXrV2FPT0WU
NB6	NGexOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTRwOE[yNFQh\|ryP	NVTaVZZ{W0GQR1XS
MDA-MB-157	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\iXmlEPTB;ND64PFc3KM7:TR?=	NGDpNmhUSU6JRWK=
UMC-11	MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDzR3RKSzVyPUSuPFg6PjRizszN	MlqxV2FPT0WU
HCC1419	NWTIOpN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PKdmlEPTB;ND65NFA3OyEQvF2=	M2DPOHNCVkeHUh?=
NCI-H2029	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnKPW92UUN3ME20Mlk1OTh3IN88US=>	NWS1fnM4W0GQR1XS
LXF-289	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3H3c2lEPTB;NT6wN\|cyQSEQvF2=	MkXsV2FPT0WU
KINGS-1	NVi1fmQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYThZYQ4UUN3ME21MlA4PzR2IN88US=>	NFmxWGFUSU6JRWK=
HD-MY-Z	NVXMSnliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HYS2lEPTB;NT6yN\|k3QSEQvF2=	MVvTRW5ITVJ?
ESS-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\wXGlEPTB;NT6yOVU6PyEQvF2=	NV3FT\|BSW0GQR1XS
GI-1	M4mzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HqfWlEPTB;NT6yO\|kzPiEQvF2=	M4f0R3NCVkeHUh?=
RPMI-2650	Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fnRmlEPTB;NT6zOlE3KM7:TR?=	M{jzT3NCVkeHUh?=
IA-LM	NUjXNI02T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInqfo1KSzVyPUWuN\|k5PzFizszN	NGLxT4pUSU6JRWK=
KP-4	NGLkRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWGwfoFzUUN3ME21MlQ3OzN2IN88US=>	MorUV2FPT0WU
G-402	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jKVGlEPTB;NT61NVg3PSEQvF2=	MnnUV2FPT0WU
OS-RC-2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYCzfJo4UUN3ME21MlUzPjB2IN88US=>	NYCxSmlJW0GQR1XS
NCI-H1155	MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnGzTWM2OD13LkW0PVU2KM7:TR?=	M3z2fnNCVkeHUh?=
OE19	M3PLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjQTWM2OD13Lk[4OlI1KM7:TR?=	M17E[3NCVkeHUh?=
U-2-OS	M2OyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUGyNIpzUUN3ME21Mlg6ODF\|IN88US=>	NFjENpNUSU6JRWK=
SCC-15	NHHTN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTVwOUO2OlIh\|ryP	NWjJVFc1W0GQR1XS
NCI-H630	M2jVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfYNI9KSzVyPUWuPVk1ODRizszN	NFzXR4hUSU6JRWK=
PFSK-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnNPHhKSzVyPU[uNFUzPTlizszN	NWLoNY5nW0GQR1XS
NCI-H1770	NIS1d5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3H[FRkUUN3ME22MlIxQDd2IN88US=>	NHT0bIJUSU6JRWK=
SK-MEL-3	MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4WyfWlEPTB;Nj60NlkyPSEQvF2=	M2LJNnNCVkeHUh?=
LB1047-RCC	M3i2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfKTWM2OD14LkS3OlI2KM7:TR?=	MkTyV2FPT0WU
NCI-H446	NIrmUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfoSZZKSzVyPU[uOlI6OjVizszN	MVfTRW5ITVJ?
SW780	M1TVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXFTWM2OD14LkewNVg2KM7:TR?=	NHK2N5pUSU6JRWK=
NEC8	MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYW5bHRvUUN3ME22Mlc3PjNizszN	M2TVTHNCVkeHUh?=
NOMO-1	M3vEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LPeWlEPTB;Nj63PFEyOSEQvF2=	NXvGbWhRW0GQR1XS
COLO-668	NHz0fpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjUOolGUUN3ME22Mlg1Ozh5IN88US=>	NYm5Uol[W0GQR1XS
MC116	MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlP2TWM2OD14LkmzPFk4KM7:TR?=	NXyzWIlEW0GQR1XS
HCC1937	NF[5boNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjVeJRKSzVyPU[uPVkzPTFizszN	NWDHd29SW0GQR1XS
NCI-N87	M3;1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY[1Z\|RWUUN3ME23MlE6Ojl\|IN88US=>	MlS0V2FPT0WU
COLO-320-HSR	Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkn3TWM2OD15LkKyO\|M5KM7:TR?=	MmLVV2FPT0WU
HCC1806	NVi3d3dbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTdwMk[wOFQh\|ryP	NHP3Sm5USU6JRWK=
OVCAR-3	M2rvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH[5OItKSzVyPUeuN\|MxOzhizszN	MYPTRW5ITVJ?
NUGC-3	MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfkclBHUUN3ME23MlM6Pjl2IN88US=>	M2Pxe3NCVkeHUh?=
SW1783	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PpSGlEPTB;Nz60N\|E4PSEQvF2=	MUPTRW5ITVJ?
GCT	Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TWdGlEPTB;Nz61OlkxPiEQvF2=	NHHIN25USU6JRWK=
NCI-H2126	NXu4bZFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTdwN{O2NlUh\|ryP	NELxWIhUSU6JRWK=
MEL-HO	NITtVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTdwN{ewOVQh\|ryP	MmLuV2FPT0WU
CAPAN-1	M2Tt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrsfWFTUUN3ME23Mlc4OzV5IN88US=>	NVLVbZduW0GQR1XS
SW756	NG\VS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPGTWM2OD15Lke4N\|M{KM7:TR?=	MYrTRW5ITVJ?
SKG-IIIa	NXSxbVRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4T2e2lEPTB;Nz64NVg6OiEQvF2=	MnfOV2FPT0WU
HCE-T	M3;1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\OS4JKSzVyPUeuPFc4QDNizszN	MmjyV2FPT0WU
Ca-Ski	NUT4cGNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zYe2lEPTB;Nz65PVM5OyEQvF2=	M4P5XXNCVkeHUh?=
COLO-684	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITLNZlKSzVyPUiuNFE5OThizszN	MkPqV2FPT0WU
KYSE-70	M3XSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjjWpVOUUN3ME24MlA4PzJ7IN88US=>	MWXTRW5ITVJ?
TI-73	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3r6TWlEPTB;OD6yOVg2OSEQvF2=	M1\CNHNCVkeHUh?=
BT-20	NIDyN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;QeGlEPTB;OD6yOlA2OiEQvF2=	NEfRb\|FUSU6JRWK=
MHH-ES-1	NFTCU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlSxTWM2OD16LkWxPFM1KM7:TR?=	NFW2[HJUSU6JRWK=
TE-12	NEW2XXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jR[mlEPTB;OD61PVk{OSEQvF2=	NFzYNZpUSU6JRWK=
YH-13	M{nObmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jJZWlEPTB;OD62NVAxQCEQvF2=	M4TtSHNCVkeHUh?=
SF126	MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTFWWdxUUN3ME24Mlg{QDZ3IN88US=>	MVXTRW5ITVJ?
J82	NWKzfJJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlfOTWM2OD16LkmwNFM5KM7:TR?=	NV\6RWVvW0GQR1XS
RCC10RGB	NUTXUHZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnz[4oxUUN3ME24Mlk6PTZzIN88US=>	MUDTRW5ITVJ?
SK-UT-1	Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHKzZ4ZKSzVyPUmuNFQ6PDVizszN	MWfTRW5ITVJ?
LB2241-RCC	M2THRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTlwMUmxN\|ch\|ryP	NHjxR5RUSU6JRWK=
LB996-RCC	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\3R5hKSzVyPUmuNVk5QSEQvF2=	M3LBR3NCVkeHUh?=
EPLC-272H	M3TJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTlwM{e2OVch\|ryP	NFz2b2pUSU6JRWK=
CTV-1	NHr2fmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTlwNU[1N\|Ih\|ryP	MVPTRW5ITVJ?
HSC-2	M3rNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTlwNUe1OUDPxE1?	MnX3V2FPT0WU
SK-MEL-28	NELVWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVr5XmVTUUN3ME25MlYyQDl\|IN88US=>	M3nP[HNCVkeHUh?=
MMAC-SF	NVHF[o56T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPoTWM2OD17Lk[4O\|Uh\|ryP	MWnTRW5ITVJ?
CP50-MEL-B	MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7nRYlKSzVyPUmuO\|U4QDJizszN	MVPTRW5ITVJ?
HT-1080	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTlwN{e3N\|kh\|ryP	NHrjOXhUSU6JRWK=
HEC-1	M13me2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXPcmJKSzVyPUGwMlM{PTJizszN	MULTRW5ITVJ?
AGS	NIC0fFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3THdWlEPTB;MUCuN\|c1KM7:TR?=	M3vTUHNCVkeHUh?=
GAMG	M{T0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTFyLkWxOlIh\|ryP	NF7xZXFUSU6JRWK=
SW48	MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLHNWFKSzVyPUGwMlUyQDlizszN	NVjoTZVDW0GQR1XS
U031	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVuzNGVWUUN3ME2xNE42QTB6IN88US=>	NVi1OnlWW0GQR1XS
OVCAR-5	NGK3VY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLrdmJKSzVyPUGwMlY1OjlizszN	M{L3ZnNCVkeHUh?=
SF295	NXnsO\|FiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPxTWM2OD1zMD62O\|A1KM7:TR?=	Mn[0V2FPT0WU
BHT-101	M2P2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTFyLkexO\|ch\|ryP	MVPTRW5ITVJ?
VMRC-RCZ	NVf0S4d7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\BTWM2OD1zMT6zNlAyKM7:TR?=	MnLUV2FPT0WU
ACHN	MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnzdZE{UUN3ME2xNU41OjFzIN88US=>	MV3TRW5ITVJ?
NCI-H526	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nOUWlEPTB;MUGuOVA1OyEQvF2=	NUDUNo83W0GQR1XS
MN-60	NYLDUJlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\wSWlEPTB;MUGuOVM6KM7:TR?=	M1jFRXNCVkeHUh?=
NCI-H2291	M1vtdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2ja[mlEPTB;MUGuOVQ3PiEQvF2=	MUXTRW5ITVJ?
SCC-25	M1;Vfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnXfVRKSzVyPUGxMlc2PTZizszN	NIjQ[FRUSU6JRWK=
SK-MEL-2	MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUL4W4wyUUN3ME2xNU44PjN5IN88US=>	MlPuV2FPT0WU
SN12C	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfrT2p7UUN3ME2xNU46OzV3IN88US=>	Mn7uV2FPT0WU
NCI-H69	MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH32fGdKSzVyPUGyMlQzOzRizszN	M{\EcHNCVkeHUh?=
ME-180	NGHreItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojtTWM2OD1zMj63NFU1KM7:TR?=	M3LEVnNCVkeHUh?=
MC-IXC	NIWzWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTF{Lke1NVgh\|ryP	MnKwV2FPT0WU
NCI-H2347	M2i1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTF{Lke2NVQh\|ryP	NX:zVHM2W0GQR1XS
M059J	NV\J[pZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIm2PI9KSzVyPUGyMlc4OjdizszN	NWnMbmJNW0GQR1XS
A2058	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\lTIhTUUN3ME2xNk45PjhzIN88US=>	Mn\mV2FPT0WU
VA-ES-BJ	M{LxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjXOo1KSzVyPUGyMlg4QDVizszN	MnrLV2FPT0WU
Ca9-22	Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4D5OmlEPTB;MUKuPVQ2OSEQvF2=	MmLJV2FPT0WU
KNS-42	M1TtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTF{Lkm5PFQh\|ryP	M1uwenNCVkeHUh?=
LoVo	NG\RXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTF\|LkKzNVMh\|ryP	MmfMV2FPT0WU
AM-38	MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTF\|LkK1OlYh\|ryP	MmXUV2FPT0WU
NB5	Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDW[lVZUUN3ME2xN{4{PzV{IN88US=>	NFLCcZBUSU6JRWK=
L-363	M1r6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrDNml2UUN3ME2xN{41ODN\|IN88US=>	MoLlV2FPT0WU
SK-MEL-30	M3HWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7TTWM2OD1zND6wOlQ2KM7:TR?=	M4XzcHNCVkeHUh?=
NCI-H1563	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvNT4JKSzVyPUG0MlYxOzlizszN	MnntV2FPT0WU
NCI-H2228	NFrIR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fwd2lEPTB;MUSuOlA4PyEQvF2=	M2OyTnNCVkeHUh?=
MFM-223	NHTjcHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIKybI1KSzVyPUG1MlE5OTNizszN	NIXic4pUSU6JRWK=
LB831-BLC	M1vwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHGTWM2OD1zNT6yO\|Y4KM7:TR?=	NFS4[pBUSU6JRWK=
SW872	NWjucoJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rrcWlEPTB;MUWuN\|A5PiEQvF2=	M2nienNCVkeHUh?=
NCI-H522	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nCbWlEPTB;MUWuN\|MxPiEQvF2=	M{HhUHNCVkeHUh?=
EW-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTF3LkW0OlIh\|ryP	MXHTRW5ITVJ?
HN	M1\DPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXy3b\|NVUUN3ME2xOU42QTR{IN88US=>	MorPV2FPT0WU
SW837	NIn1PIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XGV2lEPTB;MUWuO\|g1PyEQvF2=	MmP1V2FPT0WU
SCC-9	NEnldFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fEbGlEPTB;MUWuPFEyPCEQvF2=	NGO1XlZUSU6JRWK=
MKN7	NE\6W3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHzT2RKSzVyPUG1Mlk4OzJizszN	MXvTRW5ITVJ?
KYSE-410	M2XSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{eyRmlEPTB;MU[uOVkyKM7:TR?=	MYTTRW5ITVJ?
SK-N-DZ	MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVv0U5NPUUN3ME2xOk43OTF4IN88US=>	MWPTRW5ITVJ?
COR-L105	NYm1[3Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTF4Lk[1Nlgh\|ryP	Mof6V2FPT0WU
LB2518-MEL	NEnOdoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEj2XlJKSzVyPUG2Mlg{QDlizszN	NHy0fWlUSU6JRWK=
OVCAR-4	NIXJW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHtNYVKSzVyPUG2Mlg5PjJizszN	NGnxXIFUSU6JRWK=
TK10	M4[5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXe1NohYUUN3ME2xOk46PDd\|IN88US=>	MWrTRW5ITVJ?
KNS-62	Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHrNHpKSzVyPUG2Mlk4PzdizszN	NInQUopUSU6JRWK=
RPMI-8866	NVu3N28{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LvTGlEPTB;MUeuNVc{OiEQvF2=	MlfOV2FPT0WU
HuP-T4	MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHK0SGNKSzVyPUG3MlI1QTVizszN	Ml3zV2FPT0WU
CGTH-W-1	MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEG0W4lKSzVyPUG3MlUzOTlizszN	M2TqUXNCVkeHUh?=
T-24	NGDIT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHUTWM2OD1zNz61N\|Q4KM7:TR?=	NIfWcFFUSU6JRWK=
HT-3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTZW3VKSzVyPUG3MlU6OTRizszN	NEC2WHdUSU6JRWK=
KS-1	NXLvPVdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjLTWM2OD1zNz62O\|Mh\|ryP	NXPvc5doW0GQR1XS
NCI-H1792	M3nsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHH3TI9KSzVyPUG3Mlc6QCEQvF2=	NVPleZlqW0GQR1XS
ABC-1	M3LEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nVS2lEPTB;MUeuPFE1OSEQvF2=	Mlf3V2FPT0WU
BPH-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DKVmlEPTB;MUiuNVY5PSEQvF2=	MUjTRW5ITVJ?
A431	M33ZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorjTWM2OD1zOD60NVI4KM7:TR?=	NXzJdYk{W0GQR1XS
T98G	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTF6LkWxOVch\|ryP	NF3tOnBUSU6JRWK=
BHY	MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\UVWlEPTB;MUiuPFY6KM7:TR?=	MYLTRW5ITVJ?
Capan-2	M1S1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvhWopKSzVyPUG4MlkxPzhizszN	MUTTRW5ITVJ?
MDA-MB-175-VII	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTF6LkmyNFkh\|ryP	NF30XVNUSU6JRWK=
CAL-27	MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTF7LkC0PFch\|ryP	NIjCfYVUSU6JRWK=
AsPC-1	NHPTbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTF7Lki2OVch\|ryP	NGrQRWxUSU6JRWK=
KU812	M2DJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3u4SmlEPTB;MUmuPVU4OyEQvF2=	MWfTRW5ITVJ?
NCI-H441	MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFL1UoVKSzVyPUKwMlAxOSEQvF2=	MnLoV2FPT0WU
Mewo	MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTJyLkGyPFgh\|ryP	M1zZN3NCVkeHUh?=
SK-MEL-24	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3T6SGlEPTB;MkCuNVQ4PyEQvF2=	NUjJO2JIW0GQR1XS
NCI-H727	NUXLdGhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3SZ5dXUUN3ME2yNE4zPzB2IN88US=>	NXPjemg6W0GQR1XS
EKVX	M16zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\OTWM2OD1{MD62NFYh\|ryP	M2nGNHNCVkeHUh?=
RT-112	M3fzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7HTWM2OD1{MD62NVIzKM7:TR?=	NYLEepRkW0GQR1XS
CAMA-1	NWrK[JJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWX0VZZxUUN3ME2yNE46QDB\|IN88US=>	Mn7PV2FPT0WU
SW900	M2DLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvPTWM2OD1{MT6wNVQ6KM7:TR?=	NHewb\|lUSU6JRWK=
NCI-H23	M3nueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XvXWlEPTB;MkGuNVI4PyEQvF2=	M1Lic3NCVkeHUh?=
SK-PN-DW	M4rj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTJzLkG2OFkh\|ryP	M{nx[XNCVkeHUh?=
BB30-HNC	MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPqTWM2OD1{MT6yO\|Q2KM7:TR?=	NXG5fo9OW0GQR1XS
VM-CUB-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYqyfY83UUN3ME2yNU4{PTN4IN88US=>	M{\jPXNCVkeHUh?=
IST-MEL1	NUjs[JJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vVO2lEPTB;MkGuN\|Y6OiEQvF2=	NXjTWoN6W0GQR1XS
CTB-1	NFXOXVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorITWM2OD1{MT60O\|U2KM7:TR?=	MYTTRW5ITVJ?
LCLC-103H	M1O1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXeyc29mUUN3ME2yNk4yPTh{IN88US=>	MYfTRW5ITVJ?
PANC-03-27	MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2q3T2lEPTB;MkKuOVE3QSEQvF2=	MXfTRW5ITVJ?
HTC-C3	M3fNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\WTWM2OD1{Mj61OVU2KM7:TR?=	MXzTRW5ITVJ?
TE-8	MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mof4TWM2OD1{Mz6yOVY2KM7:TR?=	MlzvV2FPT0WU
NCI-H292	MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTJ3LkO1N\|Yh\|ryP	MorxV2FPT0WU
COLO-680N	Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPUfW5KSzVyPUK1MlY{OjlizszN	NWftXlFkW0GQR1XS
KYSE-520	Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLyTWM2OD1{NT62OFQh\|ryP	NIrQ[JVUSU6JRWK=
NB10	M1HRZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvtcolKSzVyPUK2MlMyOTdizszN	NEPme5dUSU6JRWK=
NCI-H661	NVP6flNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlq0TWM2OD1{Nj60O\|E{KM7:TR?=	MkTFV2FPT0WU
GMS-10	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TRfGlEPTB;Mk[uPFY{QCEQvF2=	NIfYTFBUSU6JRWK=
NCI-H2122	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PJ[WlEPTB;Mk[uPVk6QCEQvF2=	MYnTRW5ITVJ?
OVCAR-8	NEDndmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rBPGlEPTB;MkeuNFY{QCEQvF2=	M1KxdHNCVkeHUh?=
DJM-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjvbGRHUUN3ME2yO{4yPDV2IN88US=>	NULncnN6W0GQR1XS
UACC-893	M2fjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXGXVZtUUN3ME2yO{46QDd6IN88US=>	MmjZV2FPT0WU
C8166	NHjVfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvITWM2OD1{OD62PVM5KM7:TR?=	MnTUV2FPT0WU
NCI-H1693	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTJ6Lk[5O\|Uh\|ryP	NVPJe2VHW0GQR1XS
TYK-nu	M2q2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHxSZhkUUN3ME2zNE4xOzR3IN88US=>	NHHkUVhUSU6JRWK=
SW1710	MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFH2cJJKSzVyPUOwMlEzPiEQvF2=	M2\GPHNCVkeHUh?=
A375	MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LQOWlEPTB;M{CuN\|I1OyEQvF2=	MWHTRW5ITVJ?
HMV-II	NV3zTWNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MomxTWM2OD1\|MT6zOVkzKM7:TR?=	MUDTRW5ITVJ?
NCI-H2087	NXyzU5p2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkS1TWM2OD1\|MT62N\|UzKM7:TR?=	NX;5XWN{W0GQR1XS
CAL-54	NFLB[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTNzLkeyOFEh\|ryP	NYLqZ3ZOW0GQR1XS
HCC70	MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTN{LkGzPFch\|ryP	NYHuS4V6W0GQR1XS
ES1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPYdGtKSzVyPUOyMlMxPjJizszN	MXrTRW5ITVJ?
NCI-H1355	MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPaTWM2OD1\|Mz6yNFQh\|ryP	NEnHRZBUSU6JRWK=
CFPAC-1	NYK5U4VLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\tTWM2OD1\|Mz6yN\|MzKM7:TR?=	NVTH[VA2W0GQR1XS
MKN28	MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYn2ZWF{UUN3ME2zN{4{QDB7IN88US=>	NFvJOJZUSU6JRWK=
HDLM-2	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvUVlNKUUN3ME2zN{43QTNzIN88US=>	NVvyb5A2W0GQR1XS
PANC-10-05	NWDEXZJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoD4TWM2OD1\|ND6xNFE1KM7:TR?=	M4G0XnNCVkeHUh?=
SAS	MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmW3TWM2OD1\|ND60OVY2KM7:TR?=	NV;lTJVMW0GQR1XS
HCC1395	MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjSTWM2OD1\|ND63NVg3KM7:TR?=	NYrNTpBrW0GQR1XS
8305C	NXnU[WpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojSTWM2OD1\|NT64OFE2KM7:TR?=	NF\IXI1USU6JRWK=
KM12	M{[y[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTN4Lke1OFch\|ryP	M4T3WnNCVkeHUh?=
SW1116	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjoRoRKSzVyPUO3MlU6QTJizszN	NGPmcXNUSU6JRWK=
SK-MEL-1	NILKOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknJTWM2OD1\|OD6zN\|g6KM7:TR?=	MYHTRW5ITVJ?
HCC2218	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPUPFJKSzVyPUO4MlY2OTlizszN	MVLTRW5ITVJ?
T84	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTN6Lke0NFkh\|ryP	MkftV2FPT0WU
ETK-1	M4CydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn:xTWM2OD1\|OT6wNlIh\|ryP	M1uxOXNCVkeHUh?=
COLO-800	MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPRTWM2OD1\|OT6zPFY5KM7:TR?=	NGTOeFhUSU6JRWK=
CAL-12T	NV;kT4dPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTN7LkWyPFEh\|ryP	NYLObVdLW0GQR1XS
ACN	NHvjOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3C[WRKSzVyPUSwMlQ6OTFizszN	NWDMXpNNW0GQR1XS
SJSA-1	M1HLRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7yTWM2OD12MT6xOVk3KM7:TR?=	NYXHUnJSW0GQR1XS
PSN1	MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTRzLkG3OFkh\|ryP	MX7TRW5ITVJ?
D-566MG	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4T6TGlEPTB;NEGuNlA5PiEQvF2=	NUHzRVRiW0GQR1XS
EGI-1	NYO2foJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYD2VFIxUUN3ME20Nk41OjhizszN	MkjKV2FPT0WU
A204	M1TXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHzTWM2OD12Mj62N\|g5KM7:TR?=	NXm4eJNYW0GQR1XS
Saos-2	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTR{LkizOlkh\|ryP	NVT1TopsW0GQR1XS
SNU-C2B	NXPvVWNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTR\|Lk[4O\|gh\|ryP	MX;TRW5ITVJ?
HLE	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHCfHNJUUN3ME20OE4xQDV4IN88US=>	Mki1V2FPT0WU
SW1463	Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLVTWM2OD12ND65PVcyKM7:TR?=	MXHTRW5ITVJ?
DSH1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWq5d2NwUUN3ME20OU4xODN\|IN88US=>	MmDuV2FPT0WU
MCF7	NX;xVIRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGryOJBKSzVyPUS1MlUxPTFizszN	M4fmcHNCVkeHUh?=
K5	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTR3Lkm0NFUh\|ryP	NUOzSXppW0GQR1XS
NCI-H358	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDHcG9LUUN3ME20O{4zOTVizszN	NGHG[FdUSU6JRWK=
NCI-H2030	M33RZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWe0[HU3UUN3ME20O{4zOzd2IN88US=>	NXXOfo96W0GQR1XS
SW948	NF;EXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjXR\|FsUUN3ME20O{41PjRizszN	M3O1[XNCVkeHUh?=
BALL-1	NUCwO4pQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoS0TWM2OD12Nz62NVY5KM7:TR?=	NU\QdGxDW0GQR1XS
TE-9	NX;Kem5yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEL6do1KSzVyPUS3Mlk2QDFizszN	M1i1O3NCVkeHUh?=
SK-N-FI	NX23RXJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjDXWtWUUN3ME20PE4xOzV6IN88US=>	NHXVNHZUSU6JRWK=
KALS-1	NUDmfY9MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIP0SpdKSzVyPUS4MlEzQDlizszN	MYTTRW5ITVJ?
HO-1-N-1	M1XuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\BdGlEPTB;NEiuO\|Q1PSEQvF2=	MVTTRW5ITVJ?
NCI-H2452	MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\4VYRKSzVyPUS5MlEyPTJizszN	NFT3e\|ZUSU6JRWK=
OC-314	NGnySpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPjenBqUUN3ME20PU43QDN2IN88US=>	NGLTcHNUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; PubMed: 26811457 Proc Natl Acad Sci U S A (A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control. caspase3 / cleaved caspase 3; PubMed: 24481442 Cell Death Dis (b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa).	26811457 24481442
Growth inhibition assay	Cell viability; PubMed: 25685063 Cancer Cell Int (C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.	25685063

In vivo

When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. ^[2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. ^[2]

Protocol

Kinase Assay: ^[1]	- Collapse Affinity determination: Binding affinities (K_i or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research: ^[1]	- Collapse Cell lines: SCLC cell lines Concentrations: 0-1 μM Incubation Time: 48 hours Method: Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO₂. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 ⁴) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG Dosages: 100 mg/kg/d Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Navitoclax (ABT-263) SDF

Molecular Weight	974.61
Formula	C₄₇H₅₅ClF₃N₅O₆S₃
CAS No.	923564-51-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03181126	Recruiting	Drug: Navitoclax\|Drug: Chemotherapy\|Drug: Venetoclax	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 27 2017	Phase 1
NCT02520778	Recruiting	Drug: Navitoclax\|Drug: Osimertinib	Advanced Lung Non-Squamous Non-Small Cell Carcinoma\|EGFR Exon 19 Deletion Mutation\|EGFR NP_005219.2:p.L858R\|EGFR NP_005219.2:p.T790M\|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma\|Stage III Lung Non-Small Cell Cancer AJCC v7\|Stage IIIA Lung Non-Small Cell Cancer AJCC v7\|Stage IIIB Lung Non-Small Cell Cancer AJCC v7\|Stage IV Lung Non-Small Cell Cancer AJCC v7	National Cancer Institute (NCI)	March 31 2016	Phase 1
NCT02591095	Completed	Drug: ABT-263	Platinum-resistant or Refractory Ovarian Cancer	Centre Francois Baclesse\|ARCAGY/ GINECO GROUP\|French Cancer Research Hospital Program	January 2016	Phase 2
NCT02079740	Recruiting	Biological: Navitoclax\|Drug: Trametinib	Advanced Malignant Solid Neoplasm\|Malignant Female Reproductive System Neoplasm\|Metastatic Malignant Solid Neoplasm\|Recurrent Lung Carcinoma\|Recurrent Malignant Solid Neoplasm\|Recurrent Pancreatic Carcinoma\|Stage III Lung Cancer AJCC v7\|Stage III Pancreatic Cancer AJCC v6 and v7\|Stage IV Lung Cancer AJCC v7\|Stage IV Pancreatic Cancer AJCC v6 and v7\|Unresectable Malignant Solid Neoplasm	National Cancer Institute (NCI)	March 7 2014	Phase 1\|Phase 2
NCT00887757	Completed	Drug: ABT-263\|Drug: gemcitabine	Solid Tumors	AbbVie\|Genentech Inc.	September 2009	Phase 1
NCT00888108	Completed	Drug: ABT-263\|Drug: Docetaxel	Solid Tumor	Abbott\|Genentech Inc.	July 2009	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
Answer:
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
Question 2:
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
Answer:
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)

Cited by 153 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Navitoclax (ABT-263) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)

Cited by 153 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Navitoclax (ABT-263) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)